Disease relevance of bromoethane

• In a 2-year NTP bioassay, Bromoethane (BE) was found to induce endometrial neoplasms in the uterus of B6C3F1 mice [; ] [1].
• Metastatic sites included most commonly the lung, lymph nodes, and ovary at unusually high rates of metastases (79% for chloroethane and 38% for bromoethane) [2].

High impact information on bromoethane

• At equimolar concentrations, Tam and tamoxifen ethyl bromide (QTam), a membrane impermeant analog of Tam, rapidly induced apoptosis in HMEC-E6 cells associated with an even more rapid decrease in phosphorylation of AKT at serine-473 [3].
• Upregulation of estrogen receptor expression in the uterus of ovariectomized B6C3F1 mice and Ishikawa cells treated with bromoethane [1].
• Chloroethane and bromoethane have been shown to cause a marked uterine tumor response in B6C3F1 mice exposed for 2 years [4].
• Early changes in sex hormones are not evident in mice exposed to the uterine carcinogens chloroethane or bromoethane [4].
• The influence of ultrasound power on the C-alkylation of phenylacetonitrile by ethyl bromide was studied under solid-liquid phase transfer catalysis in the presence of potassium hydroxide and tetrabutylammonium hydrogenosulfate [5].

Associations of bromoethane with other chemical compounds

• Derivatization of prostaglandins and thromboxane B2 using diethyl amino ethyl chloride and diethyl amino ethyl bromide improved thermospray HPLC/MS sensitivity [6].

Analytical, diagnostic and therapeutic context of bromoethane

• Photodissociation study of ethyl bromide in the ultraviolet range by the ion-velocity imaging technique [7].

References